Aurel Prifti

Array ( [id] => 19447229 [patent_doc_number] => 20240307359 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS [patent_app_type] => utility [patent_app_number] => 18/418112 [patent_app_country] => US [patent_app_date] => 2024-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41595 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18418112 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19417295 [patent_doc_number] => 20240293418 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => COMBINATION THERAPY FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/411139 [patent_app_country] => US [patent_app_date] => 2024-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45516 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18411139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20371197 [patent_doc_number] => 12478611 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-25 [patent_title] => Pharmaceutical composition for oral administration of edaravone and method of administering same [patent_app_type] => utility [patent_app_number] => 18/398241 [patent_app_country] => US [patent_app_date] => 2023-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 4 [patent_no_of_words] => 11341 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 238 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18398241 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19571769 [patent_doc_number] => 20240376061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => HETEROCYCLIC GLP-1 AGONISTS [patent_app_type] => utility [patent_app_number] => 18/534517 [patent_app_country] => US [patent_app_date] => 2023-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 75651 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18534517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111177 [patent_doc_number] => 20240122927 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE [patent_app_type] => utility [patent_app_number] => 18/528976 [patent_app_country] => US [patent_app_date] => 2023-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10567 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18528976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111146 [patent_doc_number] => 20240122896 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => LASOFOXIFENE COMBINATION TREATMENT OF ER+ BREAST CANCER THAT HAS PROGRESSED ON A CDK4/6 INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/529368 [patent_app_country] => US [patent_app_date] => 2023-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25445 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18529368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19065617 [patent_doc_number] => 20240100043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => DOSING REGIMEN FOR INJECTABLE CETIRIZINE [patent_app_type] => utility [patent_app_number] => 18/520024 [patent_app_country] => US [patent_app_date] => 2023-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12590 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18520024 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19049205 [patent_doc_number] => 20240091174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => Method Of Treating Major Depressive Disorder [patent_app_type] => utility [patent_app_number] => 18/517062 [patent_app_country] => US [patent_app_date] => 2023-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12318 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18517062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19504922 [patent_doc_number] => 12116333 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-10-15 [patent_title] => 3,3'-(hydrazine-1,2-diyl)bis(1-(naphthalen-2-yloxy)propan-2-ol) as an ecofriendly insecticidal agent against spodoptera littoralis (boisd.) [patent_app_type] => utility [patent_app_number] => 18/511800 [patent_app_country] => US [patent_app_date] => 2023-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 2976 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18511800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19196328 [patent_doc_number] => 11993554 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-05-28 [patent_title] => 3,3'-(hydrazine-1,2-diyl)bis(1-(naphthalen-2-yloxy)propan-2-ol) as an ecofriendly insecticidal agent against [patent_app_type] => utility [patent_app_number] => 18/511426 [patent_app_country] => US [patent_app_date] => 2023-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 2948 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18511426 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20451788 [patent_doc_number] => 12514831 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-06 [patent_title] => Method of treating major depressive disorder [patent_app_type] => utility [patent_app_number] => 18/508826 [patent_app_country] => US [patent_app_date] => 2023-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8012 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 147 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18508826 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19226662 [patent_doc_number] => 12006295 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-06-11 [patent_title] => 4,5-bis(4-bromophenyl)-2-(4-bromophenyl)-1-hexyl-1H-imidazole as an antimicrobial compound [patent_app_type] => utility [patent_app_number] => 18/387918 [patent_app_country] => US [patent_app_date] => 2023-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4250 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18387918 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19049258 [patent_doc_number] => 20240091227 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => Use Of 2-Phenyl-6-(1H-Imidazol-1-YL) Quinazoline For Treating Neurodegenerative Diseases, Preferably Alzheimer's Disease [patent_app_type] => utility [patent_app_number] => 18/387577 [patent_app_country] => US [patent_app_date] => 2023-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18387577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19257958 [patent_doc_number] => 12017999 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-06-25 [patent_title] => 1-[4,5-bis(4-chlorophenyl)-1-hexyl-1H-imidazol-2-yl]-2-naphthol as an antimicrobial compound [patent_app_type] => utility [patent_app_number] => 18/503823 [patent_app_country] => US [patent_app_date] => 2023-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4113 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18503823 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19202742 [patent_doc_number] => 20240174641 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING [patent_app_type] => utility [patent_app_number] => 18/493126 [patent_app_country] => US [patent_app_date] => 2023-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25878 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18493126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19032394 [patent_doc_number] => 20240082209 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING PAIN WITH WOGONIN [patent_app_type] => utility [patent_app_number] => 18/491644 [patent_app_country] => US [patent_app_date] => 2023-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10985 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18491644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20561992 [patent_doc_number] => 12564582 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-03 [patent_title] => Use of pridopidine for treating dystonias [patent_app_type] => utility [patent_app_number] => 18/489846 [patent_app_country] => US [patent_app_date] => 2023-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 64 [patent_no_of_words] => 15042 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 193 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18489846 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19003578 [patent_doc_number] => 20240067649 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => NLRP3 MODULATORS [patent_app_type] => utility [patent_app_number] => 18/488092 [patent_app_country] => US [patent_app_date] => 2023-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35333 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 1313 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18488092 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19170796 [patent_doc_number] => 20240156770 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => HIGH PENETRATION PRODRUG COMPOSITIONS OF RETINOIDS AND RETINOID-RELATED COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/488616 [patent_app_country] => US [patent_app_date] => 2023-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15427 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18488616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987680 [patent_doc_number] => 20240059649 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/488215 [patent_app_country] => US [patent_app_date] => 2023-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12281 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18488215 [rel_patent_id] =>[rel_patent_doc_number] =>)